UCBJF:OTCMKTS
UCB SA
239,14 $
arrow_downward
-0,46%(-1,10) 1D
16 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJF...
Open
239,14 $
High
239,14 $
Low
239,14 $
Mkt. cap
39,39 մլրդ
Avg. vol.
127,00
Volume
107,00
52-wk high
345,39 $
52-wk low
219,60 $
Beta
0,58
Shares outstanding
194,51 մլն
No. of employees
9 հզր
Open
239,14 $
High
239,14 $
Low
239,14 $
Mkt. cap
39,39 մլրդ
Avg. vol.
127,00
Volume
107,00
52-wk high
345,39 $
52-wk low
219,60 $
Beta
0,58
Shares outstanding
194,51 մլն
No. of employees
9 հզր
News stories
From web sources and news partners
ad-hoc-news.de
·
19 ժամ առաջ
UCB revises Bimzelx potential above EUR 7 billion: UCB stock sits 30.28 percent below its high
ad-hoc-news.de
·
1 օր առաջ
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA